BPC-157 — Evidence, Legality & Safety
BPC-157 has no FDA approval for any indication. Current evidence base, legality, safety, prohibited-sport status and provider considerations.
Evidence-based answer
BPC-157 has no FDA approval for any indication. Current evidence base, legality, safety, prohibited-sport status and provider considerations.
Regulatory status: BPC-157 is not FDA approved for any human indication. It is marketed for injury recovery and gastrointestinal claims despite the absence of large randomized human trials.
Is BPC-157 legal to compound in 2026?
As of October 15, 2026, BPC-157 cannot be lawfully compounded by a U.S. 503A pharmacy, because it is not FDA-approved, is not on the 503A bulks list, is not in FDA’s interim Category 1 and has no published human efficacy trial for any use. FDA moved it out of Category 2 in April 2026 only because its nomination was withdrawn. An FDA advisory committee voted 8–6 in July to recommend listing it for ulcerative colitis, and an interim peptide access policy reached White House review on October 14, but neither has changed the law.
Canonical answer dated October 15, 2026; the same text appears on our answers page.
How it works
Proposed mechanisms come mainly from laboratory and animal models involving angiogenesis, nitric-oxide signaling, inflammation and tissue repair. Mechanistic plausibility is not clinical proof.
Mechanism is context, not proof. A defensible claim requires human outcome data for the exact molecule, formulation, dose and population. Receptor activity alone cannot establish how much weight a patient will lose, whether an injury will heal or whether a compounded vial has the identity and potency of a trial product.
What the clinical evidence shows
The evidence base is predominantly preclinical, with no pivotal phase 3 program establishing efficacy, dose, purity or long-term safety for musculoskeletal injury or gastrointestinal disease.
| Evidence level | What exists | Interpretation |
|---|---|---|
| Published human efficacy trials | None identified | No efficacy claim for any use is supported |
| FDA review | FDA briefing for the July 2026 advisory meeting (ulcerative colitis) concluded the criteria weigh against listing | FDA staff found insufficient evidence |
| Safety data | FDA: “no, or only limited, safety-related information”; immunogenicity and impurity concerns | Harm cannot be ruled out |
| Animal and laboratory studies | Tissue-repair and gastrointestinal models | Mechanism is not proof of human benefit |
Clinical-use framework
There is no FDA-approved human dosing schedule. Online calculators are not clinical guidance.
A safe plan includes medical history, medication reconciliation, pregnancy screening where relevant, contraindication review, a written titration or administration schedule, missed-dose instructions, side-effect escalation and follow-up. Laboratory testing is individualized; a universal panel is not evidence-based for every patient, but clinicians may order testing based on symptoms, comorbidities and the medicine considered.
How to evaluate an online program
- Identify the legal entities. The marketing company, prescribing practice and dispensing pharmacy may be different organizations.
- Confirm the clinician. Look for a full name, credential, NPI where applicable and authority to practice in the patient’s state.
- Read the prescription label. Verify the exact drug, salt or base, concentration, directions, facility and beyond-use date.
- Normalize cost. Add medication, membership, visits, labs, supplies, shipping and dose surcharges.
- Match the evidence. Ask whether the offered dose and route were studied for the claimed outcome.
- Review continuity. Understand refills, cold-chain handling, replacement, pharmacy changes and cancellation.
Safety
Human safety data are inadequate. Concerns include contamination, dosing error, immune reactions, unknown effects on angiogenesis and interactions with underlying disease.
This page is educational and does not replace diagnosis or individualized prescribing. Severe symptoms, suspected overdose or a serious allergic reaction require urgent in-person evaluation.
Frequently asked questions
Is BPC-157 FDA approved?
BPC-157 is not FDA approved for any human indication. It is marketed for injury recovery and gastrointestinal claims despite the absence of large randomized human trials.
What is the strongest evidence for BPC-157?
The evidence base is predominantly preclinical, with no pivotal phase 3 program establishing efficacy, dose, purity or long-term safety for musculoskeletal injury or gastrointestinal disease.
Can a compounded or microdose product claim the same trial result?
Not automatically. The trial result applies most directly to the studied product, dose, titration, population and duration. A different formulation, route or lower dose requires its own evidence.
What should be verified before treatment?
Verify the exact product, indication, prescriber, pharmacy, concentration, dose schedule, recurring cost, commitment, follow-up plan and urgent-care instructions.
Primary sources
- FDA 503A bulk-substance evaluations Primary clinical or regulatory source
- WADA Prohibited List Primary clinical or regulatory source
Provider marketing can document what is offered; it is not used as proof of safety or comparative effectiveness. Evidence was reviewed through July 12, 2026.